Financial Results and Upcoming Conference Calls - Research Report on Ariad, Idenix, Osiris, InterMune, and Array BioPharma Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, November 6, 2013 NEW YORK, November 6, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), Osiris Therapeutics, Inc. (NASDAQ: OSIR), InterMune Inc. (NASDAQ: ITMN), and Array BioPharma, Inc. (NASDAQ: ARRY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Ariad Pharmaceuticals Inc. Research Report On October 31, 2013, Ariad Pharmaceuticals Inc. (Ariad) announced the change in date of its Q3 2013 conference call from Wednesday, November 6, 2013 to Tuesday, November 12, 2013, at 8:30 a.m. EST. The Company informed that the live webcast of the call will be available under "Investor" section of its website and the replay of the same will be available for three weeks on the same location beginning approximately two hours after completion of the call. The Full Research Report on Ariad Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/161c_ARIA] -- Idenix Pharmaceuticals Inc. Research Report On October 30, 2013, Idenix Pharmaceuticals Inc. (Idenix) reported its Q3 2013 results. Idenix registered total revenues of $19,000 in Q3 2013, compared to $32.3 million in Q3 2012. The Company posted a net loss of c.$34 million or $0.25 per diluted share compared to a net income of $4.3 million or $0.03 per diluted share in Q3 2012. Ron Renaud, Idenix's President and CEO, said, "A key objective for our development teams has been to commence a clinical trial for our nucleotide prodrug program this year. Based on the differentiated profile we've seen in our preclinical research, we believe IDX21437 has strong potential to be a key component of a fixed-dose all-oral pan-genotypic regimen, specifically in combination therapy with our NS5A inhibitor." Idenix stated that cash and cash equivalents totaled $148.8 million for Q3 2013, compared with $251.9 million in Q3 2012, which the Company expects to be sufficient to sustain its operations through December 2014. The Full Research Report on Idenix Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/c979_IDIX] -- Osiris Therapeutics, Inc. Research Report On November 1, 2013, Osiris Therapeutics, Inc. (Osiris) announced its Q3 2013 results with product revenues reported at $6.9 million, up 219.9% YoY. The Company posted a net loss of $1.7 million or $0.05 per diluted share for Q3 2013, compared to $2.9 million or $0.09 per diluted share in Q3 2012. C. Randal Mills, Ph.D., President and CEO of Osiris, said, "We have now successfully transformed Osiris from a concept into a biotechnology reality with positive cash flow, expanding product sales, a strong balance sheet, no debt and a solid pipeline. Importantly, we have accomplished this with minimal dilution to our shareholders. While these results clearly set Osiris apart in the stem cell industry, the team is focused solely on realizing the opportunities ahead of us." The Full Research Report on Osiris Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/82ba_OSIR] -- InterMune Inc. Research Report On October 30, 2013, InterMune Inc. (InterMune) reported its Q3 2013 financial results. Esbriet net revenues arrived at $19.7 million representing an increase of 161.7% YoY. The Company informed that Esbriet is its product marketed in Europe and Canada for the treatment of adult patients with mild to moderate idiopathic pulmonary fibrosis. The Company posted a net loss of $49.9 million or $0.61 per basic share compared to a net loss of $40.9 million or $0.63 per basic share in Q3 2012. Dan Welch, Chairman, CEO, and President of InterMune stated, "Notably, Esbriet revenue growth in the third quarter came from both new country launches and growth in countries where the product has been available. During the quarter we launched Esbriet in Italy and the UK, two of the five largest countries in Europe, as well as in Finland and Ireland. Esbriet revenue grew in the third quarter in countries where Esbriet had previously been launched, with Germany, France, the mid-sized European countries and Canada all reporting sequential double-digit growth." For full-year 2013, the Company revised its guidance of net revenue from Esbriet to range within $60 million to $70 million. The Full Research Report on InterMune Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/dd8c_ITMN] -- Array BioPharma, Inc. Research Report On October 31, 2013, Array BioPharma, Inc. (Array BioPharma) reported its Q1 FY 2014 results (period ended September 30, 2013). Total revenues were reported at $14.2 million, compared to $15.8 million in Q1 FY 2013. The Company posted a net loss of $15.7 million or $0.13 per diluted share, compared to a net loss of $11.8 million or $0.13 per diluted share in Q1 FY 2013. Ron Squarer, CEO of Array, stated, "Array is taking an important step today by announcing plans to initiate a Phase 3 trial in 2014 with our wholly-owned multiple myeloma asset, ARRY-520. In addition, we are excited that five registration trials are already enrolling patients with our partnered MEK inhibitors, selumetinib and MEK162, with another pivotal trial expected to start by year-end." The Full Research Report on Array BioPharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/e048_ARRY] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AnalystsCorner.com SOURCE Analysts' Corner Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
Financial Results and Upcoming Conference Calls - Research Report on Ariad, Idenix, Osiris, InterMune, and Array BioPharma
Press spacebar to pause and continue. Press esc to stop.